Administering NMT to Reestablish Infant Nasal Microbiome Diversity Following Intranasal Mupirocin Treatment

Exclusion Criteria14

• Child is a ward of the State
• Child with a diagnosis of immunodeficiency or antenatal suspicion for immunodeficiency (e.g., sibling with known immunodeficiency, genetic syndrome with known associated immunodeficiency)
• Child cannot have nasal swabs collected (due to anatomic or other clinical intervention, including nasal packing)
• Donor:
• Donor had positive COVID-19 test in prior 21 days
• Donor with signs or symptoms of respiratory illness (e.g. runny nose, congestion, fever, cough)
• Donor has been in close contact with someone in the last 7 days who had a respiratory viral infection (e.g., cold, flu)
• Donor tests positive on baseline screening test for S. aureus nasal colonization.
• Donor tests positive on baseline screening test for a respiratory pathogen.
• Donor is not able to provide written informed consent
• Donor is not able to be present at the bedside at the time of intervention.
• Donor has history of chronic sinusitis, cystic fibrosis, or an infection with a multi-drug resistant organism.
• Inability or unwillingness to complete the Donor questionnaire or a positive response to any question on the Donor questionnaire.
• Donor has smoked within the last month